Nivalis Therapeutics losses grow as clinical trials advance

BOULDER — Clinical-stage pharmaceutical company Nivalis Therapeutics Inc. (Nasdaq: NVLS) this week filed its second quarterly earnings report since becoming a publicly traded company, logging a $6.1 million cash burn for the period ending Sept. 30.

The net loss amounted to 39 cents per share and was compared with a net loss of $2.6 million for the same period a year ago. So far this year, Boulder-based Nivalis has burned through $16.3 million in all, compared with $11.2 million at the same point last year.

The increased spending for the pre-revenue company is a result…